{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:52:27Z","timestamp":1776786747551,"version":"3.51.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12026-021-09244-x","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T16:02:36Z","timestamp":1636128156000},"page":"129-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2623-166X","authenticated-orcid":false,"given":"Antonio","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-6783","authenticated-orcid":false,"given":"Francesco","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"issue":"1","key":"9244_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11239-020-02120-9","volume":"50","author":"RC Becker","year":"2020","unstructured":"Becker RC. Covid-19 treatment update: follow the scientific evidence. J Thromb Thrombolysis. 2020;50(1):43\u201353. https:\/\/doi.org\/10.1007\/s11239-020-02120-9.","journal-title":"J Thromb Thrombolysis"},{"issue":"23","key":"9244_CR2","doi-asserted-by":"publisher","first-page":"12593","DOI":"10.26355\/eurrev_202012_24057","volume":"24","author":"N Trivedi","year":"2020","unstructured":"Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020;24(23):12593\u2013608. https:\/\/doi.org\/10.26355\/eurrev_202012_24057.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"9244_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11845-020-02401-5","volume":"17","author":"F Ferrara","year":"2020","unstructured":"Ferrara F, Porta R, D\u2019Aiuto V, Vitiello A. Remdesivir and COVID-19. Ir J Med Sci. 2020;17:1\u20132. https:\/\/doi.org\/10.1007\/s11845-020-02401-5.","journal-title":"Ir J Med Sci"},{"issue":"883","key":"9244_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173373","volume":"15","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F. Correlation between renin-angiotensin system and severe acute respiratory syndrome coronavirus 2 infection: what do we know? Eur J Pharmacol. 2020;15(883): 173373. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173373.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"9244_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4081\/itjm.2020.124","volume":"14","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R. Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia. Italian Journal of Medicine. 2020;14(2):88\u201394. https:\/\/doi.org\/10.4081\/itjm.2020.124.","journal-title":"Italian Journal of Medicine"},{"issue":"262","key":"9244_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118510","volume":"1","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020;1(262): 118510. https:\/\/doi.org\/10.1016\/j.lfs.2020.118510.","journal-title":"Life Sci"},{"issue":"156","key":"9244_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105579","volume":"1","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F. Therapeutic strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci. 2021;1(156): 105579. https:\/\/doi.org\/10.1016\/j.ejps.2020.105579.","journal-title":"Eur J Pharm Sci"},{"key":"9244_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11845-020-02440-y","volume":"18","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F. Remdesivir versus ritonavir\/lopinavir in COVID-19 patients. Ir J Med Sci. 2020;18:1\u20132. https:\/\/doi.org\/10.1007\/s11845-020-02440-y.","journal-title":"Ir J Med Sci"},{"key":"9244_CR9","doi-asserted-by":"publisher","first-page":"0306","DOI":"10.1016\/j.mehy.2021.110486","volume":"110486","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, La Porta R, Ferrara F. Scientific hypothesis and rational pharmacological for the use of sacubitril\/valsartan in cardiac damage caused by COVID-19. Medical Hypotheses. 2021;110486:0306\u20139877. https:\/\/doi.org\/10.1016\/j.mehy.2021.110486.","journal-title":"Medical Hypotheses"},{"key":"9244_CR10","doi-asserted-by":"publisher","unstructured":"Vitiello A, Ferrara F, La Porta R. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?2020. https:\/\/doi.org\/10.1007\/s11845-020-02482-2","DOI":"10.1007\/s11845-020-02482-2"},{"key":"9244_CR11","doi-asserted-by":"publisher","unstructured":"Ferrara F, Vitiello A. Efficacy of synthetic glucocorticoids in COVID-19 endothelites Naunyn-Schmiedeberg\u2019s Archives of Pharmacology. 2021. https:\/\/doi.org\/10.1007\/s00210-021-02049-7","DOI":"10.1007\/s00210-021-02049-7"},{"key":"9244_CR12","doi-asserted-by":"publisher","unstructured":"Vitiello A, Pelliccia C, Ferrara F, Drugs acting on the renin\u2013angiotensin system and SARS-CoV-2, Drug Discovery Today, 2021,ISSN 1359-6446, https:\/\/doi.org\/10.1016\/j.drudis.2021.01.010.","DOI":"10.1016\/j.drudis.2021.01.010"},{"key":"9244_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.01.007","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, La Porta R, D\u2019Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 2021. https:\/\/doi.org\/10.1016\/j.humimm.2021.01.007.","journal-title":"Hum Immunol"},{"issue":"106322","key":"9244_CR14","doi-asserted-by":"publisher","first-page":"0954","DOI":"10.1016\/j.rmed.2021.106322","volume":"178","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F. Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respiratory Medicine. 2021;178(106322):0954\u20136111. https:\/\/doi.org\/10.1016\/j.rmed.2021.106322.","journal-title":"Respiratory Medicine"},{"key":"9244_CR15","doi-asserted-by":"publisher","unstructured":"Ferrara F, Vitiello A. Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient. Italian Journal of Medicine, (AOP). 2020. https:\/\/doi.org\/10.4081\/itjm.2020.1435.","DOI":"10.4081\/itjm.2020.1435"},{"key":"9244_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12012-021-09649-y","volume":"9","author":"F Ferrara","year":"2021","unstructured":"Ferrara F, Vitiello A. Scientific hypothesis for treatment of COVID-19\u2019s lung lesions by adjusting ACE\/ACE2 imbalance. Cardiovasc Toxicol. 2021;9:1\u20136. https:\/\/doi.org\/10.1007\/s12012-021-09649-y.","journal-title":"Cardiovasc Toxicol"},{"key":"9244_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-021-01855-6","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F. Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. Wien Klin Wochenschr. 2021. https:\/\/doi.org\/10.1007\/s00508-021-01855-6.","journal-title":"Wien Klin Wochenschr"},{"issue":"10","key":"9244_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.587269","volume":"25","author":"MY Wang","year":"2020","unstructured":"Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 2020;25(10): 587269. https:\/\/doi.org\/10.3389\/fcimb.2020.587269.","journal-title":"Front Cell Infect Microbiol"},{"key":"9244_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2020.104502","volume":"85","author":"N Kirtipal","year":"2020","unstructured":"Kirtipal N, Bharadwaj S, Kang SG. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect Genet Evol. 2020;85: 104502. https:\/\/doi.org\/10.1016\/j.meegid.2020.104502.","journal-title":"Infect Genet Evol"},{"key":"9244_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-021-02584-5","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Porta R, Pianesi L, Ferrara F. COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. 2021. https:\/\/doi.org\/10.1007\/s11845-021-02584-5.","journal-title":"Ir J Med Sci"},{"key":"9244_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"9244_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/cpt.1857","volume":"108","author":"B Damle","year":"2020","unstructured":"Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin Pharmacol Ther. 2020;108(2):201\u201311. https:\/\/doi.org\/10.1002\/cpt.1857.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"9244_CR23","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1096\/fj.06-5806fje","volume":"20","author":"US Sajjan","year":"2006","unstructured":"Sajjan US, Jia Y, Newcomb DCH. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J. 2006;20(12):2121\u20133.","journal-title":"FASEB J"},{"issue":"12","key":"9244_CR24","doi-asserted-by":"publisher","first-page":"e00394","DOI":"10.1128\/AAC.00394-19","volume":"63","author":"C Li","year":"2019","unstructured":"Li C, Zu S, Deng YQ. Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses. Antimicrob Agents Chemother. 2019;63(12):e00394-e419. https:\/\/doi.org\/10.1128\/AAC.00394-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"9244_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/01.ftd.0000195617.69721.a5","volume":"28","author":"EB Wilms","year":"2006","unstructured":"Wilms EB, Touw DJ, Heijerman HG. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther Drug Monit. 2006;28(2):219\u201325.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"9244_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1164\/rccm.200402-200OC","volume":"170","author":"WC Tsai","year":"2004","unstructured":"Tsai WC, Rodriguez ML, Young KS. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med. 2004;170(12):1331\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"9244_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","volume":"450","author":"O Culic","year":"2002","unstructured":"Culic O, Erakovic V, Cepelak I. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450(3):277\u201389.","journal-title":"Eur J Pharmacol"},{"issue":"25","key":"9244_CR28","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.2174\/1381612043383430","volume":"10","author":"WC Tsai","year":"2004","unstructured":"Tsai WC, Standiford TJ. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr Pharm des. 2004;10(25):3081\u201393.","journal-title":"Curr Pharm des"},{"issue":"3","key":"9244_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1183\/09031936.00089407","volume":"34","author":"R Stamatiou","year":"2009","unstructured":"Stamatiou R, Paraskeva E, Boukas K, Gourgoulianis KI, Molyvdas PA, Hatziefthimiou AA. Azithromycin has an antiproliferative and autophagic effect on airway smooth muscle cells. Eur Respir J. 2009;34(3):721\u201330.","journal-title":"Eur Respir J"},{"issue":"3","key":"9244_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1128\/AAC.01142-06","volume":"51","author":"C Cigana","year":"2007","unstructured":"Cigana C, Assael BM, Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother. 2007;51(3):975\u201381.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"9244_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1165\/rcmb.2008-0357OC","volume":"42","author":"S Halldorsson","year":"2010","unstructured":"Halldorsson S, Gudjonsson T, Gottfredsson M, Singh PK, Gudmundsson GH, Baldursson O. Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol. 2010;42(1):62\u20138.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"9244_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106053","volume":"56","author":"A Pani","year":"2020","unstructured":"Pani A, Lauriola M, Romandini A, Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Agents. 2020;56(2): 106053. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106053.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"9244_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13856","volume":"75","author":"HM Abbas","year":"2021","unstructured":"Abbas HM, Al-Jumaili AA, Nassir KF, Al-Obaidy MW, Al Jubouri AM, Dakhil BD, Abdulelah MM, Al Khames QA. Assessment of COVID-19 treatment containing both hydroxychloroquine and azithromycin: a natural clinical trial. Int J Clin Pract. 2021;75(4): e13856. https:\/\/doi.org\/10.1111\/ijcp.13856.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"9244_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106239","volume":"57","author":"P Gautret","year":"2021","unstructured":"Gautret P, Hoang VT, Lagier JC, Raoult D. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. Int J Antimicrob Agents. 2021;57(1): 106239. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106239.","journal-title":"Int J Antimicrob Agents"},{"issue":"10274","key":"9244_CR35","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(21)00149-5.","journal-title":"Lancet"},{"issue":"10279","key":"9244_CR36","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0140-6736(21)00461-X","volume":"397","author":"PRINCIPLE Trial Collaborative Group","year":"2021","unstructured":"PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397(10279):1063\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(21)00461-X.","journal-title":"Lancet"},{"issue":"4","key":"9244_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.115.003560","volume":"10","author":"Z Yang","year":"2017","unstructured":"Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Sidorova T, Luis PB, Hall L, Zhang W, Du L, Milne G, Tucker P, George AL Jr, Campbell CM, Pickett RA, Shaffer CM, Chopra N, Yang T, Knollmann BC, Roden DM, Murray KT. Azithromycin causes a novel proarrhythmic syndrome. Circ Arrhythm Electrophysiol. 2017;10(4): e003560. https:\/\/doi.org\/10.1161\/CIRCEP.115.003560.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"5","key":"9244_CR38","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1213\/00000539-199711000-00010","volume":"85","author":"AW Vogt","year":"1997","unstructured":"Vogt AW, Zollo RA. Long Q-T syndrome associated with oral erythromycin used in preoperative bowel preparation. Anesth Analg. 1997;85(5):1011\u20133.","journal-title":"Anesth Analg"},{"issue":"6","key":"9244_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.120.008662.E","volume":"13","author":"M Saleh","year":"2020","unstructured":"Saleh M, Gabriels J, Chang D, Soo Kim B, Mansoor A, Mahmood E, Makker P, Ismail H, Goldner B, Willner J, Beldner S, Mitra R, John R, Chinitz J, Skipitaris N, Mountantonakis S, Epstein LM. Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythm Electrophysiol. 2020;13(6): e008662. https:\/\/doi.org\/10.1161\/CIRCEP.120.008662.E.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"2","key":"9244_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106024","volume":"56","author":"CC Lai","year":"2020","unstructured":"Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents. 2020;56(2): 106024. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106024.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"9244_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/diagnostics11040698","volume":"11","author":"M Di Domenico","year":"2021","unstructured":"Di Domenico M, De Rosa A, Boccellino M. Detection of SARS-COV-2 proteins using an ELISA Test. Diagnostics (Basel). 2021;11(4):698. https:\/\/doi.org\/10.3390\/diagnostics11040698.","journal-title":"Diagnostics (Basel)"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09244-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-021-09244-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09244-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T07:58:12Z","timestamp":1643788692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-021-09244-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["9244"],"URL":"https:\/\/doi.org\/10.1007\/s12026-021-09244-x","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"28 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No available supporting data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}